A Phase 1 Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation in Children, Adolescents and Young Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma
| Protocol No. | PHO-NYMC-ALLO-T-DART | Scope | National |
|---|---|---|---|
| Principal Investigator | April Rahrig | Treatment Type | Treatment |
| Age Group | Children | Phase | Phase I |
